FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren? Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee

This study is currently Recruiting

October 2011 By Anchen Pharmaceuticals, Inc

First Recieved on October 18, 2011

Last Updated on October 20, 2011

Sponsor: Anchen Pharmaceuticals, Inc
Collaborators: Novum Pharmaceutical Research Services
Information provided by: Anchen Pharmaceuticals, Inc
Identifier: NCT01456611

Purpose

The objective of this study is to evaluate the clinical equivalence and safety of the Test formulation of diclofenac sodium topical gel 1% (Anchen Pharmaceuticals, Inc.) compared to the marketed formulation Voltaren? Gel (diclofenac sodium topical gel) 1% (Novartis) in patients with osteoarthritis of the knee. The efficacy of both the Test and Reference formulations will also be compared to the Placebo gel to determine Superiority.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Eligibility

Ages Eligible for Study:35 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: 1. Ambulatory Male and Non Pregnant Females 35 years and older diagnosed with osteoarthritis (according to the American College of Rheumatology Criteria) in one or both knees. ACR Criteria includes, Knee Pain and at least 3 of the following: 1. age ? 50 2. stiffness lasting < 30 mins 3. bony tenderness 4. crepitus 5. bony enlargement 6. no palpable warmth 2. Symptom onset of > 6 Months prior to Screening for the target knee. 3. If female and of child-bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom + spermicide, IUD, oral, transdermal, injected or implanted hormonal contraceptives). 4. Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc) requiring the use of oral or topical treatments (NSAIDS or acetaminophen) for > 15 days in the 30 days prior to Screening. 5. Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease based upon the Kellgren-Lawrence disease severity scale. 6. After a 7 day wash out of all pain medication has baseline pain on movement score of ? 50mm on a 100-mm Visual Analogue Scale for the target knee. 7. After a 7 day wash out of all pain medication has baseline WOMAC pain sub scale of ? 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee. 8. Willing and able to use only acetaminophen as rescue medication 9. Willing and able to comply with the study requirements. Exclusion Criteria: 1. Females who are pregnant, breast feeding, or planning a pregnancy 2. Radiograph of the target knee within the previous year with a Grade 4 score on the Kellgren-Lawrence disease severity scale. 24 3. History of osteoarthritis in the contralateral knee requiring medication (OTC or prescription) within 12 months of screening. 4. After a 7 day wash out of all pain medication has baseline pain on movement score of ? 20mm on a 100-mm Visual Analogue Scale for the contralateral knee immediately prior to randomization. 5. Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty arthritis) or rheumatoid arthritis. 6. Known history of other chronic inflammatory diseases, (e.g.,colitis) or fibromyalgia. 7. History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease. 8. History of coronary artery bypass graft within 6 months of screening. 9. Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (max 162mg daily) taken for at least 3 months prior to enrollment and maintained throughout the duration of the study. 10. Use of warfarin or other anticoagulant therapy within 30 days of screening. 11. Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of screening or during the study. 12. Known history of gastrointestinal bleeding or peptic ulcer disease. 13. Abnormal screening clinical laboratory evaluations which the Investigator determines are clinically significant. 14. Known allergy to aspirin or NSAIDs. 15. Results from liver function tests that are more than two times the upper limit of the normal range at screening. 16. Any other acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the Patient at risk by participating in the study. 17. Concomitant use of corticosteroids (any formulation) or use within 30 days of study randomization. 18. Receipt of any drug as part of a research study within 30 days prior to screening. 19. Previous participation in this study.

Investigators

Locations

  • Novum Investigator Site

    Birmingham, Alabama United States

  • Novum Investigator Site

    Huntsville, Alabama United States

  • Novum Investigator Site

    Chandler, Arizona United States

  • Novum Investigator Site

    Mesa, Arizona United States

  • Novum Investigator Site

    Phoenix, Arizona United States

  • Novum Investigator Site

    Phoenix, Arizona United States

  • Novum Investigator Site

    Tuscon, Arizona United States

  • Novum Investigator Site

    Little Rock, Arkansas United States

  • Novum Investigator Site

    Anaheim, California United States

  • Novum Investigator Site

    Carmichael, California United States

  • Novum Investigator Site

    Garden Grove, California United States

  • Novum Investigator Site

    Long Beach, California United States

  • Novum Investigator Site

    Sacramento, California United States

  • Novum Investigator Site

    San Diego, California United States

  • Novum Investigator Site

    Stock Bridge, California United States

  • Novum Investigator Site

    Denver, Colorado United States

  • Novum Investigator Site

    Norwalk, Connecticut United States

  • Novum Investigator Site

    Stamford, Connecticut United States

  • Novum Investigator Site

    Adventura, Florida United States

  • Novum Investigator Site

    Bookville, Florida United States

  • Novum Investigator Site

    Bradenton, Florida United States

  • Novum Investigator Site

    Daytona Beach, Florida United States

  • Novum Investigator Site

    Hialeah, Florida United States

  • Novum Investigator Site

    Jupiter, Florida United States

  • Novum Investigator Site

    Miami, Florida United States

  • Novum Investigator Site

    Ormond Beach, Florida United States

  • Novum Investigator Site

    Pinellas Park, Florida United States

  • Novum Investigator Site

    Sarasota, Florida United States

  • Novum Investigator Site

    St. Petersburg, Florida United States

  • Novum Investigator Site

    Tampa, Florida United States

  • Novum Investigator Site

    Tampa, Florida United States

  • Novum Investigator Site

    Marietta, Georgia United States

  • Novum Investigator Site

    Sandy Springs, Georgia United States

  • Novum Investigator Site

    Lexington, Kentucky United States

  • Novum Investigator Site

    New Orleans1, Louisiana United States

  • Novum Investigator Site

    Hollywood, Maryland United States

  • Novum Investigator Site

    Billings, Montana United States

  • Novum Investigator Site

    Henderson, Nevada United States

  • Novum Investigator Site

    Cary, North Carolina United States

  • Novum Investigator Site

    Charlotte, North Carolina United States

  • Novum Investigator Site

    Hickory, North Carolina United States

  • Novum Investigator Site

    High Point, North Carolina United States

  • Novum Investigator Site

    Raleigh, North Carolina United States

  • Novum Investigator Site

    Salisbury, North Carolina United States

  • Novum Investigator Site

    Wilmington, North Carolina United States

  • Novum Investigator Site

    Winston-Salem, North Carolina United States

  • Novum Investigator Site

    Cleveland, Ohio United States

  • Novum Investigator Site

    Columbus, Ohio United States

  • Novum Investigator Site

    Beavercreek, Oklahoma United States

  • Novum Investigator Site

    Norman, Oklahoma United States

  • Novum Investigator Site

    Duncansville, Pennsylvania United States

  • Novum Investigator Site

    Chattanooga, Tennessee United States

  • Novum Investigator Site

    Houston, Texas United States

  • Novum Investigator Site

    Longview, Texas United States

  • Novum Investigator Site

    San Antonio, Texas United States

  • Novum Investigator Site

    Sugar Land, Texas United States

  • Novum Investigator Site

    Charlottesville, Virginia United States

  • Novum Investigator Site

    Midlothian, Virginia United States

  • Novum Investigator Site

    Newport News, Virginia United States

Conditions related to this trial:

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.